Evidence map›Paper›PMID 29061583›Full record

ArticleDrug metabolism and disposition: the biological fate of chemicals2018

Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells.

Peng-Cheng Li, Mei-Juan Tu, Pui Yan Ho, Joseph L Jilek, Zhijian Duan, Qian-Yu Zhang, Ai-Xi Yu, Ai-Ming Yu

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug metabolism and disposition: the biological fate of chemicals, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 62 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. In Vivo Fermentation Production of RNA Interference Agents.Methods in molecular biology (Clifton, N.J.) · 2025
    Article
  5. Article
  6. Review
  7. Review
  8. Natural medicinal compounds target signal transduction pathways to overcome ABC drug efflux transporter-mediated multidrug resistance in cancer.Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy · 2023
    Review
  9. Review
  10. Recombinant Technologies Facilitate Drug Metabolism, Pharmacokinetics, and General Biomedical Research.Drug metabolism and disposition: the biological fate of chemicals · 2023
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Review
  16. Review
  17. Development of targeted therapy of NRF2Cellular signalling · 2021
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Peng-Cheng LiDepartment of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (P.-C.L., A.-X.Y.) and Department of Biochemistry and Molecular Medicine, Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California (P.-C.L., M.-J.T., P.Y.H., J.L.J., Z.D., Q.-Y.Z., A.-M.Y.).
Mei-Juan TuDepartment of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (P.-C.L., A.-X.Y.) and Department of Biochemistry and Molecular Medicine, Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California (P.-C.L., M.-J.T., P.Y.H., J.L.J., Z.D., Q.-Y.Z., A.-M.Y.).
Pui Yan HoDepartment of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (P.-C.L., A.-X.Y.) and Department of Biochemistry and Molecular Medicine, Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California (P.-C.L., M.-J.T., P.Y.H., J.L.J., Z.D., Q.-Y.Z., A.-M.Y.).
Joseph L JilekDepartment of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (P.-C.L., A.-X.Y.) and Department of Biochemistry and Molecular Medicine, Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California (P.-C.L., M.-J.T., P.Y.H., J.L.J., Z.D., Q.-Y.Z., A.-M.Y.).
Zhijian DuanDepartment of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (P.-C.L., A.-X.Y.) and Department of Biochemistry and Molecular Medicine, Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California (P.-C.L., M.-J.T., P.Y.H., J.L.J., Z.D., Q.-Y.Z., A.-M.Y.).
Qian-Yu ZhangDepartment of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (P.-C.L., A.-X.Y.) and Department of Biochemistry and Molecular Medicine, Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California (P.-C.L., M.-J.T., P.Y.H., J.L.J., Z.D., Q.-Y.Z., A.-M.Y.).
Ai-Xi YuDepartment of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (P.-C.L., A.-X.Y.) and Department of Biochemistry and Molecular Medicine, Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California (P.-C.L., M.-J.T., P.Y.H., J.L.J., Z.D., Q.-Y.Z., A.-M.Y.) yuaixi@whu.edu.cn aimyu@ucdavis.edu.
Ai-Ming YuDepartment of Orthopedics, Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China (P.-C.L., A.-X.Y.) and Department of Biochemistry and Molecular Medicine, Comprehensive Cancer Center, UC Davis School of Medicine, Sacramento, California (P.-C.L., M.-J.T., P.Y.H., J.L.J., Z.D., Q.-Y.Z., A.-M.Y.) yuaixi@whu.edu.cn aimyu@ucdavis.edu.
Zhongnan Hospital of Wuhan University · CNWuhan University · CN

Funding

Staff InvestigatorsP30CA093373 · NCI · UNIVERSITY OF CALIFORNIA DAVIS · PI KC KENT LLOYD · 2002 to 2026
$84.9M
Predoctoral Training in Pharmacological SciencesT32GM099608 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HELL, JOHANNES W · 2012 to 2021
$2.2M
MicroRNA-1291 in Regulation of Xenobiotic Disposition and Cell DifferentiationU01CA175315 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI YU, AIMING · 2014 to 2018
$1.6M
Recombinant microRNAs in xenobiotic dispositionR01GM113888 · NIGMS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI YU, AIMING · 2016 to 2019
$1.3M
NCI NIH HHS P30 CA093373NCI NIH HHS U01 CA175315NIGMS NIH HHS R01 GM113888NIGMS NIH HHS T32 GM099608
6 · The paper itself

Abstract

The nuclear factor (erythroid-derived 2)-like 2 (NRF2) is a transcription factor in the regulation of many oxidative enzymes and efflux transporters critical for oxidative stress and cellular defense against xenobiotics. NRF2 is dysregulated in patient osteosarcoma (OS) tissues and correlates with therapeutic outcomes. Nevertheless, research on the NRF2 regulatory pathways and its potential as a therapeutic target is limited to the use of synthetic small interfering RNA (siRNA) carrying extensive artificial modifications. Herein, we report successful high-level expression of recombinant siRNA against NRF2 in

Indexed as

Antineoplastic AgentsATP-Binding Cassette TransportersBioengineeringCell Line, TumorDown-RegulationDrug Resistance, NeoplasmGene Knockdown TechniquesHeme Oxygenase-1HumansMolecular Targeted TherapyNAD(P)H Dehydrogenase (Quinone)NF-E2-Related Factor 2OsteosarcomaOxidative StressReactive Oxygen SpeciesRNA, MessengerAntineoplastic AgentsATP-Binding Cassette TransportersHeme Oxygenase-1HMOX1 protein, humanNAD(P)H Dehydrogenase (Quinone)NFE2L2 protein, humanNF-E2-Related Factor 2NQO1 protein, humanReactive Oxygen SpeciesRNA, MessengerRNA, Small Interfering

Identifiers

PMID29061583
PMCPMC5733456
OpenAlexW2766507915

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.